NBTX VS GNFT Stock Comparison

Performance

NBTX
51/100

NBTX returned -7.36% in the last 12 months. Based on the other stocks in its sector with an average return of -7.41%, its performance is above average giving it a grade of 50 of 100.

GNFT
10/100

GNFT returned -17.91% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Sentiment

NBTX
63/100

NBTX had a bullish sentiment score of 63.40% across Twitter and StockTwits over the last 12 months. It had an average of 30.90 posts, 5.83 comments, and 30.90 likes per day.

GNFT
50/100

GNFT had a bearish sentiment score of 50.00% across Twitter and StockTwits over the last 12 months. It had an average of 2.00 posts, 0.00 comments, and 0.00 likes per day.

Volatility

NBTX
20/100

NBTX has had a lower than average amount of volatility over the last 12 months giving it a grade of 20 of 100.

GNFT
54/100

GNFT has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

Technicals

NBTX

"Technicals" not found for NBTX

GNFT
57/100

GNFT receives a 57 of 100 based on 14 indicators. 7 are bullish, 5 are bearish.

Profit

NBTX

"Profit" not found for NBTX

GNFT
60/100

Out of the last 4 quarters, GNFT has had 0 profitable quarters and has increased their profits year over year on 0 of them.

All score calculations are broken down here to help you make more informed investing decisions

Nanobiotix S.A. American Depositary Shares Summary

Nasdaq / NBTX

Healthcare

Biotechnology

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

GENFIT S.A. American Depositary Shares Summary

Nasdaq / GNFT

Healthcare

Biotechnology

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Power up your portfolio